Yu Kataoka

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines

Yu Kataoka, Toru Mukohara, Hiroyuki Shimada et al. · Annals of Oncology · 2009 · 233 citations · Full text

Medicine, Genetics, Oncology +16

Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks

Yu Kataoka, Toru Mukohara, Hideo Tomioka et al. · Investigational New Drugs · 2011 · 118 citations

Medicine, Oncology, Pharmacology +16

TYRO3 as a potential therapeutic target in breast cancer.

Roudy Chiminch Ekyalongo, Toru Mukohara, Yohei Funakoshi et al. · PubMed · 2014 · 32 citations

Life Sciences, Molecular Biology, Oncology +17

Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification

Hideo Tomioka, Toru Mukohara, Yu Kataoka et al. · International Journal of Oncology · 2012 · 27 citations · Full text

Medicine, Oncology, Pharmacology +16

Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line

Yohei Funakoshi, Toru Mukohara, Hideo Tomioka et al. · Investigational New Drugs · 2013 · 23 citations

Medicine, Cancer Biology, Oncology +15